NCT01594619已完成1 期
An Open-label, Sequential, 3-period Study to Assess the Effects of Diltiazem on the Pharmacokinetics of Naloxegol in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- Description of the pharmacokinetic (PK) profile for naloxegol in terms of maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC).
研究概览
简要总结
Study in healthy volunteers to investigate the effects of Diltiazem on the Pharmacokinetics of naloxegol.
详细描述
An Open-label, sequential, 3-period study to Assess the Effects of Diltiazem on the Pharmacokinetics of Naloxegol in Healthy Subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Provision of signed and dated, written informed consent prior to any study-specific procedures.
- •Male and female (nonchildbearing potential, nonlactating) healthy volunteers aged 18 to 55 years inclusive, with suitable veins for cannulation or repeated venipuncture.
- •Female volunteers must have negative pregnancy test (screening and admission), must not be lactating, and must be of nonchildbearing potential, confirmed at screening by being postmenopausal, or documentation of irreversible surgical sterilization not in.
- •Male volunteers should be willing to use barrier contraception ie, condoms, from the first day of dosing until 3 months after dosing with the IP. The female partner should use contraception during this period.
- •Volunteers must have a BMI between 18 and 30 kg/m2, inclusive, and weigh at least 50 kg.
排除标准
- •Any clinically significant disease or disorder (eg, cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine) which, may put the volunteer at risk of participation in the study, or influence of the ADME of drugs.
- •Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IP.
- •Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results as judged by the Investigator.
- •Significant orthostatic reaction at enrolment, as judged by the Investigator.
- •Abnormal vital signs, after 10 minutes supine rest as defined in protocol.
研究组 & 干预措施
A
Experimental
Single dose naloxegol 25mg
干预措施: Naloxegol (Drug)
B
Active Comparator
Diltiazem 240mg once daily day 4-6
干预措施: Diltiazem XR (Drug)
C
Active Comparator
Diltiazem 240mg once daily day 7 and 8. Single dose naloxegol 25mg day 7
干预措施: Naloxegol (Drug)
C
Active Comparator
Diltiazem 240mg once daily day 7 and 8. Single dose naloxegol 25mg day 7
干预措施: Diltiazem XR (Drug)
结局指标
主要结局
Description of the pharmacokinetic (PK) profile for naloxegol in terms of maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC).
时间窗: At predose on Days 1 and 7 and then at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose
次要结局
- Description of the safety profile in terms of adverse events, clinical laboratory assessments , vital signs (blood pressure and pulse rate), physical examinations, electrocardiograms, and Columbia-Suicide Severity Rating scale(From baseline day 1 through to Follow-up (Maximum 21 days))
- Description of the pharmacokinetic (PK) profile for naloxegol in terms of time to Cmax (tmax), terminal half-life (t1/2λz), terminal rate constant (λz).(At predose on Day 1 and 7 and then at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose)
- Description of the pharmacokinetic (PK) profile for naloxegol in terms of area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-t)].(At predose on Day 1 and 7 and then at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose)
- Description of the pharmacokinetic (PK) profile for naloxegol in terms of area under the plasma concentration-time curve from time zero to 24hours postdose [AUC(0 24)].(At predose on Day 1 and 7 and then at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose)
- Description of the pharmacokinetic (PK) profile for naloxegol in terms of apparent oral clearance from plasma (CL/F), and apparent volume of distribution during the terminal phase (Vz/F)(At predose on Day 1 and 7 and then at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/A5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and Its Metabolites in Healthy SubjectsHealthy SubjectsNCT01261156Eisai Inc.24
已完成
1 期
A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy SubjectsThrombosisNCT02807909Bristol-Myers Squibb28
已完成
1 期
A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and DigoxinPainNCT05541471Vertex Pharmaceuticals Incorporated37
已完成
1 期
Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy SubjectsHealthyNCT04736927Galapagos NV14
已完成
1 期
Study in Healthy Volunteers to Assess the Pharmacokinetics of Midazolam Administered Alone and in Combination With VandetanibHealthy VolunteersNCT01544140Sanofi16